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ABSTRACT 
Justification and objectives: oral antineoplastic therapy has advantages compared to other 
therapies for the treatment of cancer, as it is administered at home, in a simple and fast way. 
However, this therapy increases patients’ responsibility for their treatment, and compliance is 
critical to its effectiveness. Few studies are evident regarding pharmacotherapeutic follow-up 
in oral antineoplastic therapy. In this context, this study seeks to assess adherence to tamoxifen 
treatment in women with breast cancer, before and after pharmacotherapeutic follow-up. 
Methods: this is a randomized, quantitative clinical study. Data collection was carried out for 
six months. Random randomization was divided into a control group and a follow-up group, 
with the follow-up subdivided into before and after follow-up. The follow-up group received 
individual pharmaceutical interventions monthly. Adherence was assessed by The Brief 
Medication Questionnaire, Brazilian version and drug-related problems as to necessity, 
effectiveness, and safety. Results: after pharmaceutical follow-p, a difference was observed 
between the follow-up group and the control group regarding physical activity (p=0.043), 
treatment adherence (p=0.006), reduction of side effects (p=0.003) and associated diseases 
(p=0.002). The most frequent drug-related problems were safety and adherence, for which 54 
pharmaceutical interventions were performed. The side effects described by patients mainly 
affected the genital system and gastrointestinal tract. Conclusion: it was evident that 
pharmacotherapeutic follow-up effectively contributed to adherence to treatment with 
tamoxifen and the pharmaceutical interventions performed contributed to prevention and 
reduction of drug-related problems. 
Descriptors: Medication Adherence; Antineoplastic Agents, Hormonal; Pharmaceutical 





Cancer is a public health problem, with high incidence and morbidity and mortality, 
requiring care and consequences for patients and families. Among women, breast cancer is the 
most prevalent in Brazil and in the world, with the exception of cases of non-melanoma skin 
cancer. Between 2018 and 2019, an estimated 56.33 new cases per 100 thousand women, in the 
South Region it rises to 73.07 per 100 thousand women.1  
Breast cancer treatment varies according to the stage of the disease, its biological, 
clinical and sociodemographic characteristics. Treatment modalities include local treatment 
such as surgery and radiation therapy, and systemic treatment with chemotherapy, hormone 
therapy and biological therapy.2 Oral hormone therapy comprises an important part of treatment 
associated with increased long-term survival and reduced risk of recurrence and mortality.2,3 
Among the hormonal drugs used in breast cancer, tamoxifen (TMX), a selective estrogen 
receptor modulator, is the most used.3,4 
The use of oral antineoplastic therapy has advantages such as not requiring venous 
access, treatment at home or at work without compromising patients’ usual routine, with simple 
and quick administration.5 On the other hand, this therapy increases patients’ responsibility for 
treatment and adherence becomes essential for its effectiveness. A systematic review identified 
adherence between 41 to 88% of TMX users and treatment discontinuation between 15 to 20% 
in the first year of use and 31 to 60% after five years.3 In this context, there is a need for 
pharmaceutical guidance and follow-up. The pharmacist, due to his or her strategic position, 
between the physician and the patient, can contribute to patient compliance and well-being, by 
detecting, preventing and solving drug-related problems (DRP) and other patient health 
conditions.5,6 
Few studies have been identified that address the practice of follow-up or 
pharmaceutical care for patients with breast cancer using oral hormonal therapy. This study 




The research followed an outline of a randomized clinical study conducted with women 
diagnosed with breast cancer using TMX. They were randomized into two groups: control and 
follow-up. The research was carried out in an oncology clinic located next to a hospital in a city 
in the state of Rio Grande do Sul, Brazil.  
The study sample consisted of women over the age of 18, diagnosed with breast cancer, 
using TMX, registered and seen at the oncology clinic, who lived in the city of the study and 
 
agreed to participate in the research. Women were identified from the access to the 
database/medical record of the referred hospital, in March 2016, and after that, a telephone 
contact was made to invite the participation of this research. All women who met the 
aforementioned inclusion criteria were included and those with an outdated phone or address 
were excluded. In addition, the number of participants to compose the sample was obtained for 
convenience, subject to the assessment capacity of a single investigator. He collected data and 
performed interventions as a way of reducing possible variations observed.  
The research was carried out between June and November 2016. 40 women using TMX 
were identified in the clinic’s database, of which 21 were included in the study. Data collection 
at the oncology clinic, in a private room, through a follow-up form consisting of 
sociodemographic variables, health conditions, information on pharmacotherapy and an 
instrument for assessing treatment adherence.  
Sociodemographic variables were age, education, marital status, and occupational 
activity. Education level was classified as low for those with incomplete elementary school, 
complete elementary school and incomplete high school and high for complete high school, 
incomplete higher education or complete higher education. Health conditions assessed the 
presence of associated diseases, physical activity, use of prescription and self-medication, use 
of self-reported medicinal plants and DRPs. In relation to the practice of physical exercises, 
those who reported practicing at least three times a week were considered practitioners. 
Medicinal plants were considered users who reported using infusion/decoction or macerated 
with plants daily. DRPs were classified as necessity, effectiveness, and safety, according to the 
Granada Consensus.7 
Participants were randomized randomly into control group (CG) and follow-up group 
(FG). For analysis purposes, FG was divided into two subgroups: before follow-up (FG1) and 
after follow-up (FG2). FG was followed up monthly and individual pharmaceutical 
interventions were proposed to improve patients’ pharmacotherapy, while CG was exempt from 
interventions. Pharmacotherapy assessment was performed at the initial assessment and after 
six months, being categorized into CG1 in the initial assessment and CG2 in the final 
assessment. For randomization purposes, the results regarding treatment adherence were used 
through The Brief Medication Questionnaire (BMQ), Brazilian version. This questionnaire was 
applied on the first day of service, and was divided between the two adherent and non-adherent 
groups into CG and FG.  
BMQ is a self-report method used to identify barriers to adherence in terms of regimen, 
beliefs and recall in relation to pharmacological treatment from patients’ perspective. This 
 
method classifies individuals into four categories in relation to treatment adherence, according 
to the number of positive responses in any of the domains. These categories are high adherence 
(no positive response); likely high adherence (a positive response); likely low adherence (two 
positive responses); and low adherence (three or more positive responses) in any domain.8 For 
purposes of the study, it was stratified into high adherence and likely high adherence as 
adherents, and likely low adherence and low adherence as non-adherent. The investigation of 
side effects to the medication was based on patients’ self-report. 
The data obtained were compiled in tables using the Statistical Package for the Social 
Sciences (SPSS), version 18.0. Simple descriptive analysis resources were used. For the 
quantitative variables, measures of central tendency (mean) and dispersion (standard deviation) 
were used, and for the qualitative variables, relative and absolute frequency. The normality of 
the variables was verified by the Kolmogorov-Smirnov test. To verify the association between 
two or more qualitative variables, Fisher’s exact hypothesis test was used, and for quantitative 
variables, the Mann-Whitney test was used to compare means for nonparametric and 
independent samples. For all tests, p <0.05 was considered statistically significant. 
The study followed all ethical principles involving research with human beings. The 
Research Ethics Committee approved the study, under Opinion 016287/2016 and CAAE 




Twenty-one women participated in the study, 11 in FG and 10 in CG. The mean age of 
the participants was 49.38 ± 8.1 years. The variables that describe the sociodemographic profile 
of CG and FG1 participants are described in Table 1. There was a higher frequency of people 
under 60 years of age. A higher percentage of study participants (57.14%) had low education 
both in CG and FG, with a statistical difference between these groups in this variable (p=0.024). 
The same statistical relationship was not observed regarding the marital status of patients in 
both groups, among whom more than half were married (66.66%). In relation to the 
occupational activity of the participants, 15 (71.42%) declared themselves housewives or 
retired and 6 (28.57%) were employed. 
 
Table 1. Sociodemographic profile of patients using TMX from a hospital in the state of Rio Grande do Sul, 2016 
  FG CG 
p** 














AD - adherent; N.AD - non-adherent; CG - control group; FG – follow-up group; * p <0.05, Fischer’s exact test; 
**Between CG and FG. 
As for the discovery of breast cancer, 13 patients (61.9%) reported that they discovered 
the disease through self-examination; five women (23.8%) reported that it was due to clinical 
examination; two patients (9.5%) answered that it was by another type of exam; in addition to 
those mentioned, a patient (4.8%) informed that it was through the Family Health Strategy 
(FHS). 
The clinical profile of the women participating in the study is shown in Table 2. There 
was an improvement in treatment adherence (p=0.006) in FG when compared to CG at the end 
of the follow-up, in FG adherence increased from 54.5% to 90.9%, while in CG it remained at 
40%. In addition, there was a statistically significant difference in the practice of physical 
activity (p=0.043) in reporting side effects (p=0.003) and in terms of presenting other 
comorbidities besides cancer (p=0.002) between FG and CG.  
 
Table 2. Assessment of groups and between groups before and after follow-up regarding characteristics related to 
treatment, 2016 
n(%) n(%) n(%) 
Age Up to 60 years old 4(66.7) 5(100) 6(100) 3(75) 
0.538 
Older than 60 years  2(33.3) 0 (0.0) 0(0.0) 1(25) 
Marital status Wih a companion 4(66.7) 3(60.0) 2(33.3) 0(0.0) 
0.056 
Without a companion 2(33.3) 2(40.0) 4(66.7) 4(100) 
Education level Low 2(33.3) 0(0.0) 4(66.7) 3(75) 
0.024* 
High 4(66.7) 5(100) 2(33.3) 1(25) 
Professional activity Employed 2(33.3) 3(60.0) 2(33.3) 0(0) 
0.221 
Unemployed 4(66) 2(40.0) 4(66.7) 4(100) 
  FG 
p* 
CG 










Yes 6(54.5) 10(90.9) 0.455 4(40.0) 4(40.0) - 0.006 
No 5(45.5) 1(9.1) 6(60.0) 6(60.0) 
Use of medications 
 
One 1(9.1) 2(18.2) 0.182 0(0.0) 4(40.0) - 0.286 
> 1 10(9.1) 9(81.8) 10(100) 6(60.0) 
Physical activity practice 
 
Yes 7(63.6) 8(72.7) 0.088 3(30.0) 3(30.0) - 0.043 
No 4(36.4) 3(27.3) 7(70.0) 7(70.0) 
 
SF: start of follow-up; EF: end of follow-up; II: initial interview; FI: final interview; *Analysis between before 
and after follow-up; Fischer’s exact; **Analysis between FG and CG; Fischer’s exact. 
  
Table 3 shows patients stratified regarding adherence and non-adherence to treatment, 
regardless of FG and CG. There was no difference regarding the mean number of drugs in use 
(p=729), reports of side effects (p=0.952) and time of use of TMX (p=0.691). 
 
Table 3. Assessment of patients regarding adherence to treatment with TMX and its association with the number 






Number of drugs in use 2.3±1.2 4.6±4.3 0.729 
Number of self-reported side effects 2.9±1.6 3.6±2.7 0.952 
Time of use of TMX 1.6±1.1 1.8±1.2 0.691 
M = mean; SD = standard deviation; TMX = tamoxifen; *Mann-Whitney. 
 
Regarding DRPs, there was a predominance of those classified as safety, related to side 
effects to medications (Table 4). The data show that in nine cases, patients were referred to the 
physician; in three patients, drug interaction with TMX was identified; three reported side 
effects; 11 cases were given pharmaceutical guidelines; and 11 patients were instructed on the 
risk of self-medication. Only five guidelines were not accepted by patients.  
Among the side effects reported by the participants during the follow-up, it was found 
that the most frequent were those that affected the genital system (44 - 40.0%), followed by the 
gastrointestinal tract (19 - 17.3%), nervous system (17 - 15.5%), integumentary system (14 - 
12.7%), urinary system (13 - 11.8%) and cardiac system (3 - 2.7%). 
During the study period, 54 pharmaceutical interventions were performed, as well as 
interventions of non-pharmacological measures for the resolution and prevention of DRPs. 
Among these, those related to the practice of physical activities, healthy eating and the rational 
consumption of medicinal plants stand out. These interventions took place in verbal and written 
Use of plants Yes 9(81.8) 4(36.4) 0.382 9(90.0) 7(70.0) 0.003 0.090 
No 2(18.2) 7(63.6) 1(10.0) 3(30.0) 
Side effects 
 
Yes 2(18.2) 1(9.1) 0.182 2(20.0) 2(20.0) - 0.003 
No 9(81.8) 10(90.9) 8(80.0) 8(80.0) 
Associated diseases Yes 2(18.2) 4(36.4) 0.197 5(50.0) 5(50.0) - 0.002 
No 9(81.8) 7(63.6) 5(50.0) 5(50.0) 
 
form, with the delivery of an information pamphlet on the use and storage of medications. 
Medical referrals were made in writing and reinforced by telephone contact, when necessary.  
 
Table 4. Identified DRPs and pharmaceutical interventions performed in FG. n=11, 2016 
DRP Problem Conduct N Outcome 
SAFETY DRP  









Interaction with food 
and nausea 
Guidance to administer two 
hours after breakfast 
3 





Care with medication 
storage 
Pharmaceutical education on 
the storage, administration and 
care of TMX and other 
medications in use 
11 
Improved storage 
Heart failure by 
Herceptin® 
(Trastuzumab) 












Reduced risk of 
potential drug 
interaction 
Health problem from 
not taking the 
medication correctly 
Pharmaceutical guidance on 
the correct use of TMX 11 
Reported taking 
medication every day 
at the correct time 
 
Fasting TMX in the morning 
7 
Reduction of the risk of 
potential drug 
interaction 
NECESSITY DRP  
 
Use of painkillers 
Guidance on self-medication 
12 
Decreased use of 
medication and 
minimized the 
possibility of MI 




 It is evident from the results of the present study that the performance of pharmaceutical 
care promoted an improvement in adherence to drug treatment with oral antineoplastic agents, 
since in FG, adherence increased significantly when compared to CG. The pharmacist’s 
performance also helped in adherence to non-drug treatment, as in the practice of physical 
activity. 
With regard to the profile of the participants, most are in the age group below 60 years, 
this finding is in line with the literature.9,10 Low education level was also a frequent 
characteristic, education is an important sociodemographic condition in the proposition 
pharmaceutical guidelines, as lower levels of education may be associated with a lack of 
knowledge about methods of prevention and early detection of breast cancer. Moreover, the 
level of education impacts access to basic health services and treatment, since patients with 
higher schooling tend to describe symptoms better, making their journey through the health 
system easier.11 
Concerning marital situation, most of the study participants were married or in a stable 
relationship, it is noteworthy that the partner has an important role in the woman’s life, 
supporting in coping with the disease from diagnosis to the end of treatment. In addition, 
married women generally take over the role of home caregiver, carrying out preventive exams 
and health care.11 
Regular practice of physical activity showed a significant difference between FG and 
CG, which demonstrated that pharmaceutical interventions also helped to promote non-
pharmacological treatments. Regular practice of physical activity is important during the 
treatment of women with breast cancer. A meta-analysis showed that physical activity in post-
diagnosis significantly reduced the risk of death for all causes and deaths related to breast 
cancer.12 
Cancer patients are potential candidates to discontinue the use of oral antineoplastic 
agents, especially women in advanced stage of breast cancer, as treatment requires changes in 
behavior and in living standards.4 In this context, it is emphasized that adherence to treatment 
does not it is related only to access, but it is influenced by several personal, social and structural 
factors of patients.13 As well as it depends on the bond between patients and health 
professionals, guidelines and actions that improve patients’ quality of life. The present study 
demonstrated that the pharmacotherapeutic follow-up, and the approximation between patient 
and pharmacist, improved adherence to pharmacotherapy, and consequently improves the 
expected therapeutic result. 
 
With regard to the rate of adherence of the studied patients, it is similar to the findings 
of a systematic review in which adherence varied from 41 to 88% among patients using oral 
hormone therapy.3 In Japan, a study identified that 85% of women were adherent to treatment.14 
In Brazil, 45% of respondents at Arthur de Siqueira Cavalcanti State Institute of Hematology 
(HEMORIO) were adherent to treatment.5 While in a highly complex hospital in oncology in 
Muriaé, MG it was found that 85.2 % were adherent.4 Differences in percentages between 
studies may be related to the methods of determining adherence used such as reviewing records 
in dispensing databases, reviewing medical records, or applying questionnaires to patients.8 In 
this study, a validated questionnaire, the BMQ method, was used, which may justify the 
difference between study results.  
Moreover, a systematic review noted that discontinuation in the first year is around 15 
to 20% and this figure rises to 31 to 60% at the end of five years.3 Association between treatment 
time and reduced adherence was also observed in a study carried out in New Zealand with 1,230 
women. In the assessment after one year of treatment with TMX ,90% were adherent, with two 
years, 84%, at three years, 81%, at four years, 76%, and at five years, only 50%.15 These 
findings in nursing literature demonstrate that the longer the treatment time the greater the risk 
of patients giving up treatment.15 It may also be associated with the severity of the disease, 
presence of other associated diseases and even side effects, producing different responses to 
treatment.6 No association was observed between treatment time and adherence. However, it 
appears that the mean time of use was greater than one year and these patients were not followed 
up until the end of treatment, which makes this analysis difficult and presents itself as a 
limitation. 
Among the factors associated with non-adherence, a research carried out in New 
Zealand showed that the occurrence of side effects and low tolerability with therapy.15 In Brazil, 
forgetfulness was found to be the main reason among 27 participants.16 The authors also show 
that other factors such as lack of information about the disease and lack of understanding about 
how to use the drugs were remedied with intervention. In the present study, it was evidenced 
that pharmaceutical interventions improved adherence to treatment, since participants reported 
the need for more information about the disease and medications, and that side effects and 
forgetfulness were the main causes non-adherence, which sought to remedy with guidance and 
resolution of DRPs.  
In this study, 95% of the participants reported occurrence of side effects. In a research 
carried out with postmenopausal women revealed vasomotor, gynecological, or other side 
effects among 48% of women who received TMX.17 Recurring effects in these women may 
 
also be related to chemotherapy treatment, performed prior to treatment with TMX. Therefore, 
some reported side effects are probably the remaining effects of chemotherapy and also the 
drugs used concomitantly with chemotherapy and cannot be associated exclusively with the use 
of TMX.17  
In a study conducted in New York, it was identified that 67% of patients using hormone 
therapy reported side effects.18 The authors also show that although the side effects are 
bothersome, discussions with patients about them remain below ideal, with this, highlight the 
need for health professionals to address this issue with their patients in order to improve quality 
of life and medication adherence. 
During follow-up, it was possible to reduce DRPs through pharmaceutical interventions, 
especially those related to side drug effects (safety DRPs). FG participants received guidance 
about these reactions, inherent to the mechanism of action of TMX, and were instructed to seek 
out the oncologist in specific cases. Non-pharmacological measures such as guidance of oral 
and topical hydration to help improve the dryness of the skin; regular consultation with the 
gynecologist to assess abnormal discharge; regular practice of physical exercises to help reduce 
the frequency of hot flashes and improve the emotional state; healthy eating to control weight 
and improve immunity were pharmaceutical guidelines performed and may have collaborated 
to reduce the frequency of this type of DRPs. Also, they may have contributed to the reduction 
of side effects observed at the end of the follow-up. 
 Pharmaceutical interventions to reduce and prevent DRPs have been shown to be 
effective in different settings and have contributed to safety of drug therapy and, consequently, 
of patients. A review of this topic pointed out that pharmaceutical interventions help to control 
side effects.19 As a study conducted in France that sought five educational objectives (gaining 
knowledge, improving communication skills, managing anxiety, managing side effects and 
improving adherence) identified that educational programs help patients to adhere to and live 
with the effects of endocrine therapy.20 It was observed that the use of medicinal plants as a 
complementary treatment was frequent, but there was no difference between the groups. This 
shows that this practice continued after pharmaceutical interventions, especially because it is a 
traditional practice, about which the existence of contraindications or side effects with plants is 
unknown.21 In California, a cohort of 685 women with breast cancer found that 87% used 
alternative and complementary treatment therapies.22  
Therefore, there is a need for guidance, especially in patients who use oral 
chemotherapy. It should be noted that the use of medicinal plants with TMX treatment may 
involve interactions between the drug and the plants, especially those with flavonoids and an 
 
estrogenic effect, which may increase the synergistic cytotoxicity with TMX.23 The need for 
new actions with this population is highlighted in order to provide guidance on the potential 
risks and that they need to inform the physician or pharmacist about this practice during the use 
of oral chemotherapy. In addition to plants, it is also important to provide guidance on the use 
of medications by self-medication, this practice can compromise the safety and efficacy of oral 
therapy, due to potential drug interactions and consequently side effects. 
The effectiveness of the pharmacist’s performance for the drug user is described in the 
literature. A meta-analysis on pharmaceutical care found that the pharmaceutical intervention 
reduced mortality among the patients followed.24 A research carried out in Norway has shown 
that adherence to hormone therapy is influenced by the attention paid by the health professional, 
the information received by patients and the influence of the medication on the disease, which 
reinforces the need for pharmaceutical interventions.25 
Considering the complexity of cancer treatment, at the same time its ease with the 
alternative of oral administration of treatment, the role of the pharmacist is essential in the 
treatment of cancer. In this sense, pharmaceutical assessment of the medical prescription and 
the way patients use medications can corroborate the optimization of the expected results. 
Changes in the usage process can be made from the detection of DRPs.7 
This study has as limitations the number of participants and follow-up time determined 
according to the researcher’s ability to perform as well as the lack of assessment of biochemical 
parameters that could bring other relevant information. However, it demonstrates positive 
results from the pharmacist’s clinical performance to cancer patients. This reinforces the 
conduct of new research to elucidate factors associated with adherence and which interfere with 
the effectiveness of pharmacotherapy as well as the implementation of pharmacotherapeutic 
follow-up in oncology services to ensure safety and efficacy to the prescribed treatment. 
It was evidenced that pharmacotherapeutic follow-up carried out by a pharmaceutical 
professional contributed effectively to adherence to treatment with TMX. It was identified that 
pharmaceutical interventions can prevent, prevent or reduce problems associated with 
pharmacotherapy. Thus, the clinical pharmacist through pharmacotherapeutic follow-up can 
improve the safety and effectiveness of drug treatment. 
Cancer treatment is complex because it involves emotional, social, cultural aspects and 
specific treatment conditions. Pharmacotherapeutic follow-up is a fundamental intervention 
strategy. Follow-up constitutes a space for forming a bond between patient and pharmacist, 
thereby facilitating the clarification of doubts about treatment and illness. Follow-up also seeks 
 
to reduce side effects and injuries resulting from cancer treatment, with a view to ensuring 
therapeutic success and improving the quality of life of cancer patients. 
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